JPMorgan Europe Research Enhanced Index Equity Active (ETR:JREE)
Germany · Delayed Price · Currency is EUR 53.63
+0.43 (0.81%)
At close: May 22, 2026
14.93% (1Y)
| Assets | 2.69B |
| Expense Ratio | 0.25% |
| PE Ratio | 10.22 |
| Dividend (ttm) | n/a |
| Dividend Yield | n/a |
| Ex-Dividend Date | n/a |
| Payout Frequency | n/a |
| Payout Ratio | n/a |
| 1-Year Return | +14.93% |
| Volume | 14,795 |
| Open | 53.51 |
| Previous Close | 53.20 |
| Day's Range | 53.44 - 53.76 |
| 52-Week Low | 44.57 |
| 52-Week High | 54.27 |
| Beta | 0.76 |
| Holdings | 158 |
| Inception Date | Oct 10, 2018 |
About JREE
The Sub-Fund aims to achieve a long-term return in excess of MSCI Europe Index (Total Return Net) (the "Benchmark") by actively investing primarily in a portfolio of European companies.
Asset Class Equity
Category Total Market
Stock Exchange Deutsche Börse Xetra
Ticker Symbol JREE
Provider JPMorgan
Performance
JREE had a total return of 14.93% in the past year, including dividends. Since the fund's inception, the average annual return has been 11.12%.
Top 10 Holdings
23.45% of assets| Name | Symbol | Weight |
|---|---|---|
| ASML Holding N.V. | ASML | 4.54% |
| AstraZeneca PLC | AZN | 2.61% |
| Shell plc | SHEL | 2.38% |
| Siemens Aktiengesellschaft | SIE | 2.22% |
| HSBC Holdings plc | HSBA | 2.15% |
| Nestlé S.A. | NESN | 2.12% |
| Allianz SE | ALV | 2.02% |
| Roche Holding AG | ROP | 1.90% |
| Novartis AG | NOVN | 1.89% |
| Banco Santander, S.A. | SAN | 1.62% |